World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
72
Citations
46533
World Ranking
19741
National Ranking
382

Olov Wiklund publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Olov Wiklund sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 224 publications — 5th percentile

5% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Olov Wiklund D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Olov Wiklund sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 72 D-Index — 2nd percentile

2% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Olov Wiklund is affiliated with the University of Gothenburg in Sweden and has contributed to the field of medicine, with particular focus on surgery, immunology, endocrinology, diabetes and metabolism, epidemiology, and cancer research. Their research work is centered on cardiovascular health, lipoproteins, metabolic diseases, and related genetic and biomedical topics.

Their primary research topics include:

  • Lipoproteins and Cardiovascular Health
  • Atherosclerosis and Cardiovascular Diseases
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Cancer, Lipids, and Metabolism
  • Adipokines, Inflammation, and Metabolic Diseases
  • Cardiovascular Health and Risk Factors
  • Genetics, Bioinformatics, and Biomedical Research

Wiklund's frequent publication venues are:

  • European Heart Journal
  • Atherosclerosis
  • Russian Journal of Cardiology
  • European Journal of Preventive Cardiology
  • Laboratory Service

Some of their recent scientific papers include:

  • Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel, 2020, European Heart Journal
  • 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, 2020, Russian Journal of Cardiology
  • Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM, 2020, Atherosclerosis
  • Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning, 2020, European Journal of Preventive Cardiology
  • Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM, 2021, Laboratory Service

Collaborations have been an aspect of their scientific activity, with frequent co-authors including:

  • Alberico L. Catapano
  • M. John Chapman
  • Jan Borén
  • Børge G. Nordestgaard
  • Gerald F. Watts

Best Publications

  • 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

    A Halliday;C Baigent;F Mach;B Mihaylova;B Mihaylova

  • 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

    Frank L J Visseren;François Mach;Yvo M Smulders;David Carballo

  • Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

    Brian A Ference;Henry N Ginsberg;Ian T. Graham;Kausik K Ray

  • ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)☆☆☆

    Alberico L. Catapano;Zeljko Reiner;Guy De Backer;Ian Graham

  • Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

    Borge G. Nordestgaard;M. John Chapman;Steve E. Humphries;Henry N. Ginsberg

  • Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

    Erik S. Stroes;Paul D. Thompson;Alberto Corsini;Georgirene D. Vladutiu

  • Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

    Jan Borén;M. John Chapman;M. John Chapman;Ronald M. Krauss;Chris J. Packard

  • 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

    Massimo F. Piepoli;Arno W. Hoes

  • Subendothelial retention of atherogenic lipoproteins in early atherosclerosis.

    Kristina Skålén;Maria Gustafsson;Ellen Knutsen Rydberg;Lillemor Mattsson Hultén

  • T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein.

    Sten Stemme;Beata Faber;Jan Holm;Olov Wiklund

  • Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

    Marina Cuchel;Eric Bruckert;Henry N. Ginsberg;Frederick J. Raal

  • Familial Hypercholesterolaemia in Children and Adolescents: Gaining Decades of Life by Optimizing Detection and Treatment

    Albert Wiegman;Samuel S. Gidding;Gerald F Watts;M John Chapman

  • Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points - A joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

    Børge G. Nordestgaard;Anne Langsted;Samia Mora;Genovefa Kolovou

  • The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management

    Robert A. Hegele;Henry N. Ginsberg;M. John Chapman;Børge G. Nordestgaard

  • The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent

    Rosellina Margherita Mancina;Paola Dongiovanni;Salvatore Petta;Piero Pingitore

  • Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes.

    Eeva Leinonen;Eva Hurt-Camejo;Olov Wiklund;Lillemor Mattson Hultén

  • Statin use and non-alcoholic steatohepatitis in at risk individuals

    Paola Dongiovanni;Salvatore Petta;Ville Mannisto;Rosellina Margherita Mancina

  • PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells

    Carlo Pirazzi;Luca Valenti;Benedetta Maria Motta;Piero Pingitore

  • Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

    François Mach;Kausik K Ray;Olov Wiklund;Olov Wiklund;Alberto Corsini

  • Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro

    Carlo Pirazzi;Martin Adiels;Maria Antonella Burza;Rosellina Margherita Mancina

Frequent Co-Authors

Marja-Riitta Taskinen
Marja-Riitta Taskinen University of Helsinki
Alberico L. Catapano
Alberico L. Catapano University of Milan
Ian D. Graham
Ian D. Graham Ottawa Hospital
Piotr Ponikowski
Piotr Ponikowski Wrocław Medical University
Naveed Sattar
Naveed Sattar University of Glasgow
Victor Aboyans
Victor Aboyans University of Limoges
Stephan Windecker
Stephan Windecker University of Bern
Héctor Bueno
Héctor Bueno Spanish National Centre for Cardiovascular Research
José Luis Zamorano
José Luis Zamorano Hospital Ramon y Cajal
Eva Prescott
Eva Prescott University of Copenhagen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA can open doors to a variety of rewarding paths beyond the traditional MD route. For those interested in healthcare leadership, pursuing the cheapest online master degree in healthcare administration can be a cost-effective starting point. This credential prepares graduates for management roles in hospitals, clinics, and public health organizations.

Nurses seeking to advance their practice may consider one of the most affordable dnp programs to earn a Doctor of Nursing Practice online. DNP degrees are designed for those aiming for leadership, clinical, or academic roles within nursing.

Pharmacy is another healthcare field experiencing high demand. Convenient and reputable pharmacy degree online options let students prepare for licensure while balancing work and other commitments.

Lastly, managing medical data is crucial in modern healthcare, and pursuing online rhit degree programs can lead to careers as Registered Health Information Technicians (RHITs). Each pathway offers flexibility, affordability, and a direct link to impactful roles in healthcare.

Best Scientists Citing Olov Wiklund

Trending Scientists

Recently Published Articles